XML 35 R14.htm IDEA: XBRL DOCUMENT
v3.22.2.2

FAIR VALUE MEASUREMENTS | 9 Months Ended
--- | ---
Sep. 30, 2022
Fair Value Disclosures [Abstract] |
FAIR VALUE MEASUREMENTS | FAIR VALUE MEASUREMENTS Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. The Company prioritizes the inputs used to determine fair values in one of the following three categories: Level 1—Quoted market prices in active markets for identical assets or liabilities. Level 2—Inputs, other than quoted prices in active markets, that are observable, either directly or indirectly. Level 3—Unobservable inputs that are not corroborated by market data. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, the level in the fair value hierarchy within which the fair value measurement in its entirety falls has been determined based on the lowest level input that is significant to the fair value measurement in its entirety. The consolidated condensed financial statements include financial instruments for which the fair market value of such instruments may differ from amounts reflected on a historical cost basis. Financial instruments of the Company consist of cash deposits, accounts and other receivables, investments, accounts payable, certain accrued liabilities, and borrowings under a revolving credit agreement. The carrying value of these financial instruments generally approximates fair value due to their short-term nature. Financial instruments also include notes payable. As of September 30, 2022, the fair value of the notes payable, based on Level 2 inputs, was $560.8 million. Assets and Liabilities Measured at Fair Value on a Recurring Basis The following table summarizes the Company's financial instruments which are measured at fair value on a recurring basis (in millions):
September 30, 2022 | Level 1 |  | Level 2 |  | Level 3 |  | Total
Assets |  |  |  |  |  |  |
Cash equivalents | $ | 16.7 |  |  | $ | 144.6 |  |  | $ | — |  |  | $ | 161.3 |
Available-for-sale investments: |  |  |  |  |  |  |
Corporate debt securities | — |  |  | 1,068.5 |  |  | — |  |  | 1,068.5 |
Asset-backed securities | — |  |  | 432.8 |  |  | — |  |  | 432.8 |
United States government and agency securities | 38.5 |  |  | 97.7 |  |  | — |  |  | 136.2 |
Municipal securities | — |  |  | 2.5 |  |  | — |  |  | 2.5 |
Investments held for deferred compensation plans | 104.1 |  |  | — |  |  | — |  |  | 104.1 |
Derivatives | — |  |  | 156.8 |  |  | — |  |  | 156.8 |
| $ | 159.3 |  |  | $ | 1,902.9 |  |  | $ | — |  |  | $ | 2,062.2 |
Liabilities |  |  |  |  |  |  |
Derivatives | $ | — |  |  | $ | 4.4 |  |  | $ | — |  |  | $ | 4.4 |
Deferred compensation plans | 104.1 |  |  | — |  |  | — |  |  | 104.1 |
Contingent consideration liabilities | — |  |  | — |  |  | 25.7 |  |  | 25.7 |
Other liability | — |  |  | — |  |  | 14.0 |  |  | 14.0 |
| $ | 104.1 |  |  | $ | 4.4 |  |  | $ | 39.7 |  |  | $ | 148.2 |
December 31, 2021 |  |  |  |  |  |  |
Assets |  |  |  |  |  |  |
Cash equivalents | $ | 15.2 |  |  | $ | 30.7 |  |  | $ | — |  |  | $ | 45.9 |
Available-for-sale investments: |  |  |  |  |  |  |
Bank time deposits | — |  |  | 2.5 |  |  | — |  |  | 2.5 |
Corporate debt securities | — |  |  | 1,390.8 |  |  | — |  |  | 1,390.8 |
Asset-backed securities | — |  |  | 512.6 |  |  | — |  |  | 512.6 |
United States government and agency securities | 28.4 |  |  | 118.9 |  |  | — |  |  | 147.3 |
Commercial paper | — |  |  | 127.7 |  |  | — |  |  | 127.7 |
Municipal securities | — |  |  | 2.8 |  |  | — |  |  | 2.8 |
Investments held for deferred compensation plans | 130.7 |  |  | — |  |  | — |  |  | 130.7 |
Derivatives | — |  |  | 55.3 |  |  | — |  |  | 55.3 |
| $ | 174.3 |  |  | $ | 2,241.3 |  |  | $ | — |  |  | $ | 2,415.6 |
Liabilities |  |  |  |  |  |  |
Derivatives | $ | — |  |  | $ | 3.9 |  |  | $ | — |  |  | $ | 3.9 |
Deferred compensation plans | 130.9 |  |  | — |  |  | — |  |  | 130.9 |
Contingent consideration liabilities | — |  |  | — |  |  | 62.0 |  |  | 62.0 |
Other liability | — |  |  | — |  |  | 14.0 |  |  | 14.0 |
| $ | 130.9 |  |  | $ | 3.9 |  |  | $ | 76.0 |  |  | $ | 210.8 |
Cash Equivalents and Available-for-sale Investments The Company estimates the fair values of its money market funds based on quoted prices in active markets for identical assets. The Company estimates the fair values of its time deposits, commercial paper, United States and foreign government and agency securities, municipal securities, asset-backed securities, and corporate debt securities by taking into consideration valuations obtained from third-party pricing services. The pricing services use industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades and broker-dealer quotes on the same or similar securities, benchmark yields, credit spreads, prepayment and default projections based on historical data, and other observable inputs. The Company independently reviews and validates the pricing received from the third-party pricing service by comparing the prices to prices reported by a secondary pricing source. The Company’s validation procedures have not resulted in an adjustment to the pricing received from the pricing service. Deferred Compensation Plans The Company holds investments in trading securities related to its deferred compensation plans. The investments are in a variety of stock, bond and money market mutual funds. The fair values of these investments and the corresponding liabilities are based on quoted market prices. Derivative Instruments The Company uses derivative financial instruments in the form of foreign currency forward exchange contracts and cross currency swap contracts to manage foreign currency exposures. All derivatives contracts are recognized on the balance sheet at their fair value. The fair value of the derivative financial instruments was estimated based on quoted market foreign exchange rates, cross currency swap basis rates, and market discount rates. Judgment was employed in interpreting market data to develop estimates of fair value; accordingly, the estimates presented herein are not necessarily indicative of the amounts that the Company could realize in a current market exchange. The use of different market assumptions or valuation methodologies could have a material effect on the estimated fair value amounts. Contingent Consideration Liabilities Certain of the Company's acquisitions involve contingent consideration arrangements. Payment of additional consideration is contingent upon the acquired company reaching certain performance milestones, such as attaining specified sales levels or obtaining regulatory approvals. These contingent consideration liabilities are measured at estimated fair value using either a probability weighted discounted cash flow analysis or a Monte Carlo simulation model, both of which consider significant unobservable inputs. These inputs as of September 30, 2022 include (1) the discount rate used to present value the projected cash flows (ranging from 2.8% to 12.3%; weighted average of 4.1%), (2) the probability of milestone achievement (ranging from 0% to 50%; weighted average of 39.6%), (3) the projected payment dates (2026), and (4) the volatility of future sales (ranging from 45.0% to 55.0%; weighted average of 55.0%). The weighted average of each of the above inputs was determined based on the relative fair value of each obligation. The use of different assumptions could have a material effect on the estimated fair value amounts. The following tables summarize the changes in fair value of the contingent consideration and the other liability (in millions):
| Contingent Consideration |  | Other liability |  | Total
Balance at December 31, 2021 | $ | 62.0 |  |  | $ | 14.0 |  |  | $ | 76.0 |
Changes in fair value | (36.3) |  |  | — |  |  | (36.3) |
Balance at September 30, 2022 | $ | 25.7 |  |  | $ | 14.0 |  |  | $ | 39.7 |
| Contingent Consideration |  | Other liability |  | Total
Balance at December 31, 2020 | $ | 186.1 |  |  | $ | — |  |  | $ | 186.1 |
Additions | — |  |  | 14.0 |  |  | 14.0 |
Changes in fair value | (106.0) |  |  | — |  |  | (106.0) |
Balance at September 30, 2021 | $ | 80.1 |  |  | $ | 14.0 |  |  | $ | 94.1 |
The contingent consideration liabilities related to certain of the Company's previous business acquisitions were reduced in the nine months ended September 30, 2022 by $30.9 million due to both the changes in projected probabilities of milestone achievement and the Company's decision during the third quarter of 2022 to exit its HARPOON surgical mitral repair system program (see Note 3). The contingent consideration liabilities were reduced in the nine months ended September 30, 2021 by $105.2 million due to changes in the projected probabilities and timing of milestone achievements and the projected timing of cash inflows.

X
- References No definition available. + Details
Name: | us-gaap_FairValueDisclosuresAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -URI https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258 + Details
Name: | us-gaap_FairValueDisclosuresTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration